Company: PRGO
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001585364-25-000056
Chunk: 56

Company: PERRIGO Co plc
Filing Date: 2025-05-07
Form: 10-Q
Item: Item 1
Chunk 56
---
 net lost distribution of lower margin products within U.S. Store Brand. These were partially offset by higher net sales in the Nutrition category of $14.5 million, stemming from recovery in the infant formula business, as well as higher net sales in the Upper Respiratory category due primarily to higher incidence levels of cough cold compared to the prior year period and improved supply of key products.

CSCA net sales by product category were as follows:

SalesThree Months Ended(in millions, except percentages)March 29, 2025March 30, 2024$ Change% ChangeUpper Respiratory$137.9 $130.3 $7.6 5.8 %Nutrition104.8 90.6 14.1 15.7 %Digestive Health103.0 122.2 (19.2)(15.7)%Pain and Sleep-Aids76.6 82.6 (6.0)(7.3)%Healthy Lifestyle70.4 71.3 (0.9)(1.3)%Oral Care62.0 64.7 (2.7)(4.2)%Skin Care48.6 49.6 (1.0)(2.0)%Women's Health15.0 27.2 (12.1)(44.9)%Vitamins, Minerals, and Supplements ("VMS")1.6 4.2 (2.6)(61.9)%Other CSCA0.8 1.4 (0.6)(42.9)%Total CSCA$620.7 $644.1 $(23.4)(3.6)%

Sales in each category were driven primarily by:

•Upper Respiratory: Net sales of $137.9 million increased 5.8% due primarily to higher incidence levels of cough cold compared to the prior year quarter and higher net sales of the allergy products Nasonex®, Triamcinolone Acetonide and Fluticasone. This growth was partially offset by previously disclosed net lost distribution of lower margin products. 

•Nutrition: Net sales of $104.8 million increased 15.7% due primarily to a 19% increase in net sales of infant formula products driven by continuing store brand infant formula business recovery partially offset by lower net sales in contract manufacturing and lower Good Start® brand sales to Canadian customers. 

•Digestive Health: Net sales of $